Alpha Cognition Inc
ACOG
Rankning i aktier
#20072
Alpha Cognition Inc., a biopharmaceutical company, engages in the development... Alpha Cognition Inc., a biopharmaceutical company, engages in the development of treatments for patients suffering from neurodegenerative diseases in the United States and Canada. The company's commercial development program includes ZUNVEYL oral tablet formulation for treating Alzheimer's disease. Its pre-clinical development programs comprise ZUNVEYL in combination with memantine for the treatment of moderate-to-severe Alzheimer's disease; ALPHA-1062 sublingual formulation for acute pancreatitis; ALPHA-1062 intranasal formulation for the treatment of cognitive impairment with mild traumatic brain injury; and ALPHA-0602, ALPHA-0702, and ALPHA-0802 programs for the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis disease and spinal muscular atrophy. The company was founded in 2000 and is headquartered in Vancouver, Canada.
Aktiekurs
$8.66
Senast synkroniserad: 2026-10-20
Marknadsvärde
$134.50M
Förändring (1 dag)
1.88%
Förändring (1 år)
72.17%
Land
US
Handel Alpha Cognition Inc (ACOG)
Kategori
Healthcare
Historik för aktiesplit för Alpha Cognition Inc (ACOG)
Aktien Alpha Cognition Inc (symbol: ACOG) har genomgått totalt 1 aktiesplitar.
Den senaste spliten skedde den Nov 05, 2024.
En ACOG-aktie köpt före Nov 05, 2024 motsvarar nu 0.04 ACOG-aktier.
Den senaste spliten skedde den Nov 05, 2024.
En ACOG-aktie köpt före Nov 05, 2024 motsvarar nu 0.04 ACOG-aktier.
Lista över aktiesplitar
| År | Split | Multipel | Kumulativ multipel |
|---|---|---|---|
| 2024-11-05 | 1:25 | x0.04 | x0.04 |
Aktiesplitar för liknande företag eller konkurrenter
| Företag | Antal aktiesplitar | Kumulativ multipel | Land |
|---|---|---|---|
| 1 | x2 |
US
|
|
| 0 | - |
US
|
|
| 1 | x3 |
AU
|
|
| 0 | - |
CH
|
|
| 0 | - |
NL
|
